Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAmphastar P

Amphastar P

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
28.67 USD 0.07 ( 0.24%)
Last update at 2026-11-12T15:36:00Z
VOLUME
21528
Market Cap
1039.88M
P/E
11.29

Momentum Score

…

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
28.58
Low
28.84
High
52 Week Price Range
17.03
Low
31.26
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Amphastar Pharmaceuticals, Inc. develops, manufactures and sells injectable, inhalation and other specialty generic products, primarily for the U.S. market. Long-term growth drivers include approvals of additional complex generic and inhalation products, scale in contract manufacturing and steady demand for lower-cost injectable therapies; investors may find the company attractive for its focused manufacturing capabilities and potential to diversify revenue through new approvals and contract work.

Material risks include regulatory and manufacturing compliance, reliance on a small number of products, pricing pressure in the generic market and potential litigation or reimbursement headwinds.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
28.60
Dividend Yield
-
Revenue TTM
719.89M
Revenue Per Share
15.40
Gross Profit TTM
356.06M
Debt / Equity
0.83
ROE
12.90%
Net Debt
485.82M
ROCE
9.54%
Diluted EPS TTM
2.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 123.62M 189.19M 171.36M 116.04M 84.14M
Minority interest - - 0.00M 0.00M 1.19M
Net income 98.09M 159.52M 137.54M 91.39M 62.12M
Selling general administrative 85.92M 56.72M 51.54M 45.06M 51.43M
Selling and marketing expenses 43.88M 37.80M 28.85M 21.53M 17.49M
Gross profit 356.06M 373.86M 351.12M 248.86M 199.74M
Reconciled depreciation 63.20M 57.20M 35.78M 28.74M 26.75M
Ebit - 220.11M 198.52M 78.76M 85.02M
Ebitda 149.10M 277.31M 240.29M 107.50M 111.78M
Depreciation and amortization - 57.20M 41.78M 28.74M 26.75M
Non operating income net other - - - 9.21M 14.93M
Operating income 140.40M 205.42M 196.99M 78.76M 43.13M
Other operating expenses 579.48M 526.55M 447.41M 391.49M 367.88M
Interest expense 25.48M 30.34M 27.16M 1.85M 0.89M
Tax provision 25.53M 29.67M 34.45M 23.48M 20.63M
Interest income 8.68M 10.61M 3.74M 1.32M 0.60M
Net interest income -16.80M -19.73M -14.49M -0.53M -0.28M
Income tax expense 25.53M 29.67M 31.83M 23.48M 20.63M
Total revenue 719.89M 731.97M 644.39M 498.99M 437.77M
Total operating expenses 215.65M 168.44M 154.13M 141.36M 129.85M
Cost of revenue 363.83M 358.11M 293.27M 250.13M 238.03M
Total other income expense net -16.78M -16.23M -25.63M 8.54M 14.25M
Net income from continuing ops 98.09M 159.52M 135.29M 91.39M 63.51M
Net income applicable to common shares - - - 91.39M 62.12M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1629.30M 1577.47M 1512.91M 741.99M 671.53M
Intangible assets 562.56M 587.61M 610.08M 34.17M 35.56M
Other current assets 32.75M 20.65M 9.58M 7.56M 7.27M
Total liab 840.49M 845.17M 873.49M 213.33M 226.01M
Total stockholder equity 788.80M 732.30M 639.42M 528.66M 445.52M
Deferred long term liab - - - - 0.53M
Other current liab 98.83M 126.54M 194.02M 4.57M 9.08M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings 666.88M 568.79M 409.27M 271.72M 180.34M
Other liab - - - 21.93M 22.72M
Good will 3.40M 3.05M 3.22M 3.13M 3.31M
Other assets - - - 59.38M 39.06M
Cash 170.18M 151.61M 144.53M 156.10M 126.35M
Total current liabilities 158.16M 173.76M 225.41M 94.86M 103.81M
Current deferred revenue - - 1.61M - -
Net debt 485.82M 498.94M 479.11M -53.52M -21.69M
Short term debt 9.57M 7.04M 4.34M 6.05M 5.18M
Short long term debt 1.64M 0.23M 0.44M 3.05M 2.20M
Short long term debt total 656.00M 650.55M 623.64M 102.58M 104.66M
Other stockholder equity 127.23M 172.69M 238.62M 265.55M 271.94M
Property plant equipment - - - 238.27M 244.24M
Total current assets 636.02M 534.07M 489.60M 378.32M 318.12M
Long term investments 0.00M 11.00M 15.21M 2.41M 3.98M
Net tangible assets - - - 491.36M 406.65M
Short term investments 112.64M 70.04M 114.71M 19.66M 10.32M
Net receivables 143.56M 138.04M 114.94M 88.97M 78.93M
Long term debt 608.75M 601.63M 589.58M 72.84M 74.78M
Inventory 176.89M 153.74M 105.83M 103.58M 92.81M
Accounts payable 32.59M 30.51M 25.44M 84.24M 89.55M
Accumulated other comprehensive income -5.31M -9.18M -8.48M -8.62M -6.76M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - 271.72M 180.34M
Treasury stock - - - -189.52M -150.48M
Non currrent assets other 31.14M 25.99M 25.91M 20.86M 16.66M
Non current assets total 993.28M 1043.40M 1023.31M 363.67M 353.41M
Capital lease obligations 45.61M 48.69M 33.63M 26.70M 27.68M
Long term debt total - - - 72.84M 74.78M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -28.84M -124.93M -546.30M -7.79M 1.40M
Change to liabilities - - - -0.74M 3.02M
Total cashflows from investing activities -70.33M -124.93M - -32.78M -28.67M
Net borrowings 5.99M 10.17M - -2.19M 30.36M
Total cash from financing activities -67.42M -80.95M 454.09M -26.44M -37.02M
Change to operating activities - - - -5.01M 0.37M
Net income 98.09M 159.52M 137.54M 91.39M 63.30M
Change in cash 18.57M 7.31M -11.80M 29.75M 32.08M
Begin period cash flow 151.84M 144.53M 156.33M 126.59M 94.51M
End period cash flow 170.41M 151.84M 144.53M 156.33M 126.59M
Total cash from operating activities 156.12M 213.39M 183.50M 89.18M 97.99M
Depreciation 63.20M 57.20M 41.78M 28.74M 26.75M
Other cashflows from investing activities -6.61M -4.12M 1.39M -1.37M -2.61M
Dividends paid - - 454.09M 15.66M 15.93M
Change to inventory -21.06M -48.80M -1.72M -11.75M 1.26M
Change to account receivables -6.37M -21.67M -26.09M -10.13M -14.92M
Sale purchase of stock -75.59M -85.46M -58.14M -39.91M -28.87M
Other cashflows from financing activities - -5.67M -14.11M 15.25M -40.24M
Change to netincome - - - 2.73M 8.04M
Capital expenditures 34.88M 41.04M 38.17M 24.03M 27.46M
Change receivables - - - -10.13M -14.92M
Cash flows other operating - - - -7.56M 13.81M
Cash and cash equivalents changes - - - 29.96M 32.30M
Change in working capital -65.97M -14.55M -24.21M -32.18M -1.92M
Stock based compensation 27.28M 24.37M 20.24M 17.86M 18.69M
Other non cash items 5.89M 4.71M 21.89M -0.88M -13.03M
Free cash flow 121.23M 172.34M 145.34M 65.15M 70.54M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AMPH
Amphastar P		 0.07
0.24%		 28.67 11.29 - 1.44 1.29 1.94 6.57
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Amphastar P

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

11570 6th Street, Rancho Cucamonga, CA, United States, 91730

909 980 9484

https://www.amphastar.com

1976

Name Title Year Born
Dr. Ziping Luo Ph.D. Chairman, Chief Scientist & COO 1950
Dr. Yongfeng Zhang Ph.D. Co-Founder, Pres, CEO, Chief Scientific Officer & Director 1947
Mr. William J. Peters M.B.A. CFO, Exec. VP of Fin., Treasurer & Director 1968
Mr. Jacob Liawatidewi M.B.A. Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director 1974
Mr. Rong Zhou M.S. Exec. VP of Production Center 1959
Dan Dischner M.B.A. VP of HR & Corp. Communication NA
Tony Marrs M.B.A., M.P.H. Sr. VP of Regulatory Affairs & Clinical Operations NA
Mr. Peter Langosh VP of Operational Improvement and VP of Internal Audit 1953
Dr. Ziping Luo Ph.D. Chairman of the Board, Chief Scientist & COO 1950
Dr. Yongfeng Zhang Ph.D. Co-Founder, President, CEO, Chief Scientific Officer & Director 1947

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…